Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-derived xenograft platform for metastatic melanoma

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE73738 | GEO | 2016/05/26

SECONDARY ACCESSION(S): PRJNA297786

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Patient and xenograft-derived organoids recapitulate pediatric brain tumors features and patient treatments

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-12-01 | GSE247381 | GEO

Patient-derived xenograft platform for metastatic melanoma: RNA sequencing of 95 melanoma PDX samples

Project description:Although high clinical response rates are seen for immune checkpoint blockade (ICB) of metastatic melanoma, both intrinsic and acquired ICB resistance remain formidable challenges. Combination ICB shows improved clinical benefit, but is associated with severe adverse events and exceedingly high cost. Therefore, there is a dire need to stratify individual patients for their likelihood of responding to either anti-PD-1 or anti-CTLA-4 monotherapy, or the combination. Since it is conceivable that ICB responses are influenced by both tumor cell-intrinsic and stromal factors, we hypothesized that a predictive classifier ought to mirror both of these distinct features. We used a panel of melanoma patient-derived xenografts (PDX), in which human stromal cells upon transplantation are naturally replaced by their murine counterparts, to computationally subtract PDX RNA expression signals from those in patients’ melanomas. We thus derived both “Stromal immune” (SIM) and tumor cell-specific “Tumor-autonomous inflammation” (TAF) signatures. Here we report that the SIM signature predicts response to anti-CTLA-4 but not anti-PD-1 treatment, whereas the tumor TAF signature predicts response to anti-PD-1 but not anti-CTLA-4. Moreover, when used in conjunction, the signatures accurately predict response in two independent patient cohorts treated with the anti-CTLA-4 + anti-PD-1 combination. These signatures may be clinically exploited for personalized treatment advice based on the predicted benefit from either anti-CTLA-4 or anti-PD-1 monotherapy or their combination.

2020-04-27 | GSE129127 | GEO

Patient-derived xenograft platform for metastatic melanoma: RNA sequencing of 4 melanoma PDX samples

Project description:The therapeutic landscape of melanoma is rapidly changing. While targeted inhibitors yield significant responses, their clinical benefit is often limited by the early onset of drug resistance. This motivates the pursuit to establish more durable clinical responses, by developing combinatorial therapies. But while potential new combinatorial targets steadily increase in numbers, they cannot possibly all be tested in patients. Similarly, while genetically engineered mouse melanoma models have great merit, they do not capture the enormous genetic diversity and heterogeneity typical in human melanoma. Furthermore, whereas in vitro studies have many advantages, they lack the presence of micro-environmental factors, which can have a profound impact on tumor progression and therapy response. This prompted us to develop an in vivo model for human melanoma that allows for studying the dynamics of tumor progression and drug response, with concurrent evaluation and optimization of new treatment regimens. Here, we present a collection of patient-derived xenografts (PDX), derived from BRAFV600E, NRASQ61 or BRAFWT/NRASWT melanoma metastases. The BRAFV600E PDX melanomas were acquired both prior to treatment with the BRAF inhibitor vemurafenib and after resistance had occurred, including six matched pairs. We find that PDX resemble their human donors’ melanomas regarding biomarkers, chromosomal aberrations, RNA expression profiles, mutational spectrum and targeted drug resistance patterns. Mutations, previously identified to cause resistance to BRAF inhibitors, are captured in PDX derived from resistant melanomThis melanoma PDX platform represents a comprehensive public resource to study both fundamental and translational aspects of melanoma progression and treatment in a physiologically relevant setting.

2016-05-27 | GSE73737 | GEO

Genome-wide expression profiling of melanoma cells (cancer cell lines and patient derived xenograft tumor models) treated with ARN22089 inhibitor

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-02-23 | GSE197216 | GEO

Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-07-29 | GSE155277 | GEO

Gene expression and copy number analysis of recurrent metastatic melanoma lesions

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-12-31 | E-GEOD-38187 | biostudies-arrayexpress

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-01-18 | E-GEOD-42670 | biostudies-arrayexpress

Genome scale analysis of DNA methylation patterns in prostate cancer patient derived xenograft models

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-12-31 | GSE227853 | GEO

Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-02-09 | GSE165764 | GEO

Single-cell transcriptome profiling for metastatic renal cell carcinoma patient-derived cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2015-09-18 | GSE73122 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data